{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:05:23Z","timestamp":1792011923150,"version":"4.4.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.4103\/sjmms.sjmms_101_19","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T04:50:44Z","timestamp":1566967844000},"page":"214-218","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Follicular Lymphoma: Saudi Lymphoma Group\u2019s Clinical Practice Guidelines for Diagnosis, Management and Follow-up"],"prefix":"10.4103","volume":"7","author":[{"given":"Reyad","family":"Dada","sequence":"first","affiliation":[{"name":"Department of Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia"},{"name":"College of Medicine, Al-Faisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubarak","family":"Al-Mansour","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia"},{"name":"Adult Medical Oncology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Alhashmi","sequence":"additional","affiliation":[{"name":"Adult Hematology and Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy","family":"Kandil","sequence":"additional","affiliation":[{"name":"Oncology Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia"},{"name":"Clinical Oncology Department, Cairo University, Giza, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Alhejazi","sequence":"additional","affiliation":[{"name":"Department of Oncology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Central Region, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sagheir","sequence":"additional","affiliation":[{"name":"Oncology Institute, John Hopkins Aramco Healthcare, Dhahran, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibraheem","family":"Motabi","sequence":"additional","affiliation":[{"name":"Department of Adult Hematology and BMT, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"issue":"Suppl 1","key":"R2-20250523","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jiph.2012.09.011","article-title":"The lung cancer management guidelines 2012","volume":"5","author":"Jazieh","year":"2012","journal-title":"J Infect Public Health"},{"key":"R4-20250523","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2009.26.1693","article-title":"Prognostic factors in follicular lymphoma","volume":"28","author":"Relander","year":"2010","journal-title":"J Clin Oncol"},{"key":"R5-20250523","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ajh.23674","article-title":"Follicular lymphoma: 2014 update on diagnosis and management","volume":"89","author":"Freedman","year":"2014","journal-title":"Am J Hematol"},{"key":"R6-20250523","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1309\/4KEH-AGY7-UT5H-41XJ","article-title":"CD5+ follicular lymphoma: A clinicopathologic study of three cases","volume":"118","author":"Barry","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"R7-20250523","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2006-09-045989","article-title":"CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features","volume":"109","author":"Karube","year":"2007","journal-title":"Blood"},{"key":"R8-20250523","first-page":"1543","article-title":"Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region","volume":"148","author":"Flenghi","year":"1996","journal-title":"Am J Pathol"},{"key":"R9-20250523","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1096-9896(199606)179:2<145::AID-PATH565>3.0.CO;2-1","article-title":"BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin\u2019s lymphomas","volume":"179","author":"Pittaluga","year":"1996","journal-title":"J Pathol"},{"key":"R10-20250523","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"R11-20250523","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/1097-0142(19821215)50:12<2699::AID-CNCR2820501202>3.0.CO;2-A","article-title":"Malignant lymphoma 1. The histology and staging of 473 patients at the National Cancer Institute","volume":"50","author":"Anderson","year":"1982","journal-title":"Cancer"},{"key":"R12-20250523","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular Lymphoma in the United States:First report of the National LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"R13-20250523","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R14-20250523","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3109\/10428194.2014.990010","article-title":"Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: Is it time to change the standard strategy?","volume":"56","author":"Janikova","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R15-20250523","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hon.2437_11","article-title":"CVP or R-CVP given after involved-field radiotherapy improves progression free survival in stage I-II follicular lymphoma: Results of an international randomized trial","volume":"35","author":"Macmanus","year":"2017","journal-title":"Hematol Oncol"},{"key":"R16-20250523","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","article-title":"Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: Results of an F2-study database","volume":"30","author":"Solal-C\u00e9ligny","year":"2012","journal-title":"J Clin Oncol"},{"key":"R17-20250523","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first-line management strategies for stage I follicular lymphoma: Analysis of the National LymphoCare study","volume":"30","author":"Friedberg","year":"2012","journal-title":"J Clin Oncol"},{"key":"R18-20250523","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","article-title":"Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin\u2019s lymphoma","volume":"21","author":"Seymour","year":"2003","journal-title":"J Clin Oncol"},{"key":"R19-20250523","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"R20-20250523","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon Alfa: A randomized study from the groupe d\u2019etude des lymphomes folliculaires. Groupe d\u2019etude des lymphomes de l\u2019adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"R21-20250523","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"R22-20250523","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"R23-20250523","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"R24-20250523","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"R25-20250523","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"key":"R26-20250523","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11864-006-0036-3","article-title":"Follicular lymphoma international prognostic index","volume":"7","author":"Solal-Celigny","year":"2006","journal-title":"Curr Treat Options Oncol"},{"key":"R27-20250523","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German low-grade lymphoma study group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"R28-20250523","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"key":"R29-20250523","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/jnci\/djr450","article-title":"Autologous stem cell transplantation in follicular lymphoma: A systematic review and meta-analysis","volume":"104","author":"Al Khabori","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"R30-20250523","first-page":"CD007678","article-title":"High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults","volume":"1","author":"Schaaf","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R31-20250523","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"R32-20250523","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German low-grade lymphoma study group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"R33-20250523","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"R34-20250523","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"R35-20250523","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"key":"R36-20250523","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","article-title":"Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II VERTICAL study","volume":"29","author":"Fowler","year":"2011","journal-title":"J Clin Oncol"},{"key":"R37-20250523","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","article-title":"Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German low grade lymphoma study group (GLSG)","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"R38-20250523","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"R39-20250523","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"R40-20250523","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.28243","article-title":"Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: A comprehensive analysis from the NCCN lymphoma outcomes project","volume":"119","author":"Evens","year":"2013","journal-title":"Cancer"}],"container-title":["Saudi Journal of Medicine &amp; Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjmms.sjmms_101_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:05:23Z","timestamp":1787774723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjmms.sjmms_101_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.4103\/sjmms.sjmms_101_19","relation":{},"ISSN":["1658-631X","2321-4856"],"issn-type":[{"value":"1658-631X","type":"print"},{"value":"2321-4856","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"2019-03-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}